Results 5,281-5,300 of 14,090 for speaker:Marc MacSharry
- Public Accounts Committee: Financial Statements 2016: National Treatment Purchase Fund (14 Jun 2018)
Marc MacSharry: All right. Can the NTPF control the market price?
- Public Accounts Committee: Financial Statements 2016: National Treatment Purchase Fund (14 Jun 2018)
Marc MacSharry: If one looks at the price one paid last year to somebody else, it was the NTPF that paid the price so it is not a fair comparison, particularly if the NTPF is the only buyer in the market.
- Public Accounts Committee: Financial Statements 2016: National Treatment Purchase Fund (14 Jun 2018)
Marc MacSharry: Right.
- Public Accounts Committee: Financial Statements 2016: National Treatment Purchase Fund (14 Jun 2018)
Marc MacSharry: The analysis is done against that backdrop. What is the realistic percentage?
- Public Accounts Committee: Financial Statements 2016: National Treatment Purchase Fund (14 Jun 2018)
Marc MacSharry: No. I just picked on that element because it looks a bit dodgy to me.
- Public Accounts Committee: Financial Statements 2016: National Treatment Purchase Fund (14 Jun 2018)
Marc MacSharry: Is all the required expertise available to the NTPF in terms of how much things should cost? I mean the cost per hour for so many staff, how much new beds cost, how much new equipment costs, etc.
- Public Accounts Committee: Financial Statements 2016: National Treatment Purchase Fund (14 Jun 2018)
Marc MacSharry: Can the NTPF access information on independent pricing and all of that?
- Public Accounts Committee: Financial Statements 2016: National Treatment Purchase Fund (14 Jun 2018)
Marc MacSharry: I appreciate that my next question does not fall within the remit of the NTPF but I shall ask it anyway given that the NTPF has the expertise. How can I reconcile someone paying €950 a week versus €1,400 a week? I am just taking advantage of the fact that there are experts in the room. I must ask about this matter because that is part of my role. Therefore, I am interested...
- Public Accounts Committee: Financial Statements 2016: National Treatment Purchase Fund (14 Jun 2018)
Marc MacSharry: What is it in the private sector?
- Public Accounts Committee: Financial Statements 2016: National Treatment Purchase Fund (14 Jun 2018)
Marc MacSharry: I understand. I realise that everybody is different.
- Public Accounts Committee: Financial Statements 2016: National Treatment Purchase Fund (14 Jun 2018)
Marc MacSharry: Everybody is different.
- Public Accounts Committee: Financial Statements 2016: National Treatment Purchase Fund (14 Jun 2018)
Marc MacSharry: Is a scale applied?
- Public Accounts Committee: Financial Statements 2016: National Treatment Purchase Fund (14 Jun 2018)
Marc MacSharry: Is there no scale?
- Public Accounts Committee: Financial Statements 2016: National Treatment Purchase Fund (14 Jun 2018)
Marc MacSharry: Is a metric or matrix applied?
- Public Accounts Committee: Financial Statements 2016: National Treatment Purchase Fund (14 Jun 2018)
Marc MacSharry: Yes.
- Public Accounts Committee: Financial Statements 2016: National Treatment Purchase Fund (14 Jun 2018)
Marc MacSharry: Is that part of the review?
- Public Accounts Committee: Financial Statements 2016: National Treatment Purchase Fund (14 Jun 2018)
Marc MacSharry: Good. Let us say that the HSE is correct about levels of dependency. Given their personal experience and expertise in this area, do the witnesses think that is credible? I know it is not Mr. Sloyan's role but I am interested in his view.
- Public Accounts Committee: Financial Statements 2016: National Treatment Purchase Fund (14 Jun 2018)
Marc MacSharry: When will the review be published?
- Public Accounts Committee: Financial Statements 2016: National Treatment Purchase Fund (14 Jun 2018)
Marc MacSharry: I know about the process. When does the review go to the Department?
- Public Accounts Committee: Financial Statements 2016: National Treatment Purchase Fund (14 Jun 2018)
Marc MacSharry: Do the witnesses think that the Act is fit for purpose?